Analysis of radiopharmaceuticals market size by Research Nester reveals the market to register a CAGR of ~10.2% during 2025-2037 and reach ~USD 26.6 billion by 2037.
Research Nester assesses the growth and size of the global radiopharmaceuticals market which is anticipated to account for the increasing prevalence of chronic illnesses, the need for more sophisticated tests and treatments, and the development of diagnostic imaging technology.
Rising Need for Neurological Applications to Enhance Global Market Growth
Neurological applications are rapidly gaining traction across the globe, reshaping the global radiopharmaceutical market. Factors such as the rising need for precise diagnosis and the increasing prevalence of neurodegenerative disorders including Parkinson’s and Alzheimer’s are boosting the sales of radiopharmaceuticals. Radiopharmaceuticals have become essential tools for researchers and neurologists alike, as they may provide light on the intricate workings of the brain and molecular illnesses.
some key factors and challenges associated with the radiopharmaceuticals market include:
Growth Drivers:
- Growing need for neurological applications
- Growing utilization of personalized medicine
Challenges:
Since radiopharmaceuticals guarantee productivity and security in the biotechnology and pharmaceutical industries, they are vital to healthcare institutions. However, several obstacles can prevent the business from realizing its full potential since radiopharmaceuticals are costly to develop and implement and the market might not be expanding rapidly during the forecast period.
By type, the global radiopharmaceuticals market is segmented into therapeutic and diagnostics. The diagnostics segment is expected to garner the highest revenue by the end of 2037. Radioisotopes such as fluorine-18, technetium-99m, and iodine-131 are used in imaging tools including, SPECT and PET. These isotopes are combined with radiopharmaceuticals, administered to patients, and then observed using specialized imaging equipment. Moreover, it is projected that the benefits of radioactive imaging over traditional diagnostic imaging will support the category’s expansion by 2032.
By region, the Europe radiopharmaceuticals market is anticipated to generate significant revenue during the forecast period. Growing government funding for medical imaging developments, a focus on customized medicine, and rising healthcare technology investments are all factors contributing to the growth of the radiopharmaceutical market in Europe. In targeted therapeutics and diagnostic imaging, radiopharmaceuticals are essential for bettering patient outcomes and increasing the effectiveness of healthcare delivery.
This report also provides the existing competitive scenario of some of the key players of the global radiopharmaceuticals market which includes company profiling of Bayer AG, Bracco, Cardinal Health Inc., Coquí Radiopharmaceuticals Corp, Curium Pharma, Eli Lilly and Company, General Electric Company, IRE EliT, Bristol Myers Squibb and others.
Source – https://www.researchnester.com/reports/radiopharmaceuticals-market/6519
By Aashi Mishra, Research Writer at Research Nester
Author –
Aashi Mishra
An experienced research writer, strategist, and marketer with a demonstrated history of research in a myriad of industries. I love to distill complex industrial terminologies of market space into simpler terms.